Chen Juan, Wei Yanghui, Yang Weiqin, Huang Qingnan, Chen Yong, Zeng Kai, Chen Jiawei
Department of Medicine and Rehabilitation, Tung Wah Eastern Hospital, Hong Kong, Hong Kong SAR, China.
Department of Surgery, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Front Oncol. 2022 Jul 18;12:903800. doi: 10.3389/fonc.2022.903800. eCollection 2022.
Breast cancer is one of the leading causes of mortality in females. Over the past decades, intensive efforts have been made to uncover the pathogenesis of breast cancer. Interleukin-6 (IL-6) is a pleiotropic factor which has a vital role in host defense immunity and acute stress. Moreover, a wide range of studies have identified the physiological and pathological roles of IL-6 in inflammation, immune and cancer. Recently, several IL-6 signaling pathway-targeted monoclonal antibodies have been developed for cancer and immune therapy. Combination of IL-6 inhibitory antibody with other pathways blockage drugs have demonstrated promising outcome in both preclinical and clinical trials. This review focuses on emerging studies on the strong linkages of IL-6/IL-6R mediated regulation of inflammation and immunity in cancer, especially in breast cancer.
乳腺癌是女性死亡的主要原因之一。在过去几十年里，人们为揭示乳腺癌的发病机制付出了巨大努力。白细胞介素-6（IL-6）是一种多效性因子，在宿主防御免疫和急性应激中起着至关重要的作用。此外，大量研究已经确定了IL-6在炎症、免疫和癌症中的生理和病理作用。最近，几种针对IL-6信号通路的单克隆抗体已被开发用于癌症和免疫治疗。IL-6抑制性抗体与其他通路阻断药物的联合使用在临床前和临床试验中均显示出了有前景的结果。本综述重点关注关于IL-6/IL-6R介导的炎症和免疫调节在癌症，尤其是乳腺癌中的紧密联系的新研究。
